Labiana Health

Labiana Health Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Labiana Health (LAB.MC) as of Nov 19, 2026 is 66.14 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 2,837.76 % — a change of -97.67% (lower).

Cash Conversion

66.14 %

YoY

-97.67%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Labiana Health is 2025 66.14 % . Cash Conversion Rate (OCF/Net Income) of Labiana Health was 2024 2,837.76 % . It decreases by -97.67% lower compared to the previous year.

The Labiana Health Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
163.06 EUR
Jan 1, 2019
-146.56 EUR
Jan 1, 2021
-220.05 EUR
Jan 1, 2022
-52.32 EUR
Jan 1, 2023
41.28 EUR
Jan 1, 2024
2,837.76 EUR
Jan 1, 2025
66.14 EUR
The Labiana Health Cash Conversion history
YEARCash ConversionYoY
66.14 %-97.67%
2,837.76 %+6,774.96%
41.28 %-178.90%
-52.32 %-76.22%
-220.05 %+50.14%
-146.56 %-189.88%
163.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Cash Conversion Rate (OCF/Net Income) of Labiana Health is 66.14 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Labiana Health changed from 2,837.76 % to 66.14 %, representing a -97.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Labiana Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labiana Health

All Key Metrics — Labiana Health